BR0109494A - Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas - Google Patents

Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas

Info

Publication number
BR0109494A
BR0109494A BR0109494-7A BR0109494A BR0109494A BR 0109494 A BR0109494 A BR 0109494A BR 0109494 A BR0109494 A BR 0109494A BR 0109494 A BR0109494 A BR 0109494A
Authority
BR
Brazil
Prior art keywords
human cell
production
blood clotting
factor viii
cell lines
Prior art date
Application number
BR0109494-7A
Other languages
English (en)
Other versions
BRPI0109494B8 (pt
BRPI0109494B1 (pt
Inventor
Charlotte Hauser
Andrea Hoerster
Carola Schroeder
Michael Lehnerer
Original Assignee
Octagene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Octagene Gmbh filed Critical Octagene Gmbh
Publication of BR0109494A publication Critical patent/BR0109494A/pt
Publication of BRPI0109494B1 publication Critical patent/BRPI0109494B1/pt
Publication of BRPI0109494B8 publication Critical patent/BRPI0109494B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"PRODUçãO DE FATORES RECOMBINANTES DE COAGULAçãO DO SANGUE EM LINHAS CELULARES HUMANAS". A presente invenção refere-se a um processo melhorado para a produção de fatores recombinantes de coagulação do sangue humano, em particular do fator VIII e fator IX, utilizando uma linhagem celular humana imortalizada expressando estavelmente proteínas ativadoras de transcrição viral e carregando um vetor tendo um promotor funcionalmente ligado a uma seq³ência de DNA codificando para um fator de coagulação do sangue, desde que o dito promotor não seja um promotor viral que seja estimulado pelas ditas proteínas ativadoras de transcrição viral; e linhagem celular humana imortalizada carregando o dito vetor; muteínas do fator VIII particularmente adequadas para o processo de produção acima; composições farmacêuticas compreendendo tais muteínas do fator VIII e a utilização de tais muteínas do fator VIII para a preparação de um medicamento para o tratamento de hemofilia.
BRPI0109494A 2000-03-22 2001-03-21 muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii BRPI0109494B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00106225.6 2000-03-22
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08
US60/203,249 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (en) 2000-03-22 2001-03-21 Production of recombinant blood clotting factors in human cell lines

Publications (3)

Publication Number Publication Date
BR0109494A true BR0109494A (pt) 2002-12-10
BRPI0109494B1 BRPI0109494B1 (pt) 2021-05-11
BRPI0109494B8 BRPI0109494B8 (pt) 2021-05-25

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0109494A BRPI0109494B8 (pt) 2000-03-22 2001-03-21 muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii

Country Status (28)

Country Link
US (1) US7572619B2 (pt)
EP (2) EP1460131A3 (pt)
JP (1) JP3894795B2 (pt)
KR (1) KR100581574B1 (pt)
CN (1) CN1454257B (pt)
AT (1) ATE312176T1 (pt)
AU (3) AU5471501A (pt)
BE (1) BE2014C077I2 (pt)
BG (1) BG65930B1 (pt)
BR (1) BRPI0109494B8 (pt)
CA (1) CA2404163C (pt)
CZ (1) CZ303929B6 (pt)
DE (1) DE60115613T2 (pt)
DK (1) DK1266006T3 (pt)
EA (1) EA004317B1 (pt)
EE (1) EE200200538A (pt)
ES (1) ES2254403T3 (pt)
FR (1) FR15C0003I2 (pt)
HR (1) HRP20020767B1 (pt)
HU (1) HU228091B1 (pt)
IL (2) IL151857A0 (pt)
MX (1) MXPA02009221A (pt)
NO (1) NO330910B1 (pt)
NZ (1) NZ521732A (pt)
RS (1) RS50743B (pt)
SI (1) SI1266006T1 (pt)
SK (1) SK287706B6 (pt)
WO (1) WO2001070968A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
KR100638184B1 (ko) * 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
DE602005024955D1 (de) 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
WO2006036502A2 (en) 2004-09-22 2006-04-06 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ATE541919T1 (de) * 2005-02-11 2012-02-15 Novo Nordisk Healthcare Ag Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
PT2495307T (pt) 2006-07-13 2018-05-10 Wyeth Llc Produção do fator ix de coagulação com padrão melhorado de glicosilação
EP2517714A1 (en) * 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
JPWO2009028575A1 (ja) * 2007-08-27 2010-12-02 国立大学法人名古屋大学 血液凝固第ｖｉｉ因子プロモーターの活性化剤及びその利用
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
CA2776503C (en) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
US9115381B2 (en) 2011-05-13 2015-08-25 Octapharma Ag Method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
CA2898975C (en) * 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
AP2016009663A0 (en) 2014-07-30 2016-12-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017180857A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP4352083A1 (en) 2021-06-11 2024-04-17 Sorbonne Universite Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
EP0500734B1 (en) * 1989-11-17 1998-02-11 Novo Nordisk A/S Protein complexes having factor viii:c activity and production thereof
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2073859A1 (en) 1990-01-26 1991-07-27 Falko-Guenter Falkner Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
DE69434689D1 (de) * 1993-06-10 2006-05-18 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
EP0915975A2 (en) * 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2312291A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
WO2000049147A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
SI1266006T1 (sl) * 2000-03-22 2006-06-30 Octagene Gmbh Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
SK15042002A3 (sk) 2003-09-11
YU71002A (sh) 2005-11-28
WO2001070968A2 (en) 2001-09-27
WO2001070968A3 (en) 2001-12-13
KR100581574B1 (ko) 2006-05-22
AU2001254715B2 (en) 2006-02-02
CA2404163A1 (en) 2001-09-27
HUP0300588A3 (en) 2005-09-28
EP1460131A2 (en) 2004-09-22
EE200200538A (et) 2004-04-15
ATE312176T1 (de) 2005-12-15
BG107152A (bg) 2003-06-30
CZ20023166A3 (cs) 2003-02-12
HRP20020767A2 (en) 2005-02-28
NO20024475D0 (no) 2002-09-19
ES2254403T3 (es) 2006-06-16
NO20024475L (no) 2002-11-20
BE2014C077I2 (pt) 2020-01-30
SK287706B6 (en) 2011-07-06
JP3894795B2 (ja) 2007-03-22
BRPI0109494B8 (pt) 2021-05-25
CZ303929B6 (cs) 2013-07-03
HU228091B1 (en) 2012-10-29
DE60115613D1 (de) 2006-01-12
BRPI0109494B1 (pt) 2021-05-11
BG65930B1 (bg) 2010-05-31
FR15C0003I1 (fr) 2015-02-27
CN1454257B (zh) 2013-01-16
US7572619B2 (en) 2009-08-11
EA004317B1 (ru) 2004-02-26
AU2006201848A1 (en) 2006-05-25
MXPA02009221A (es) 2005-07-25
SI1266006T1 (sl) 2006-06-30
RS50743B (sr) 2010-08-31
DE60115613T2 (de) 2006-08-24
EP1460131A3 (en) 2005-06-01
EP1266006B1 (en) 2005-12-07
IL151857A (en) 2010-05-31
EP1266006A2 (en) 2002-12-18
NZ521732A (en) 2004-05-28
HRP20020767B1 (en) 2011-09-30
US20040023333A1 (en) 2004-02-05
DK1266006T3 (da) 2006-01-16
CN1454257A (zh) 2003-11-05
AU5471501A (en) 2001-10-03
JP2003530093A (ja) 2003-10-14
KR20030011079A (ko) 2003-02-06
HUP0300588A2 (hu) 2003-06-28
CA2404163C (en) 2009-09-29
EA200201008A1 (ru) 2003-02-27
NO330910B1 (no) 2011-08-15
FR15C0003I2 (fr) 2015-11-20
IL151857A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
DE68917300T2 (de) Heilung von wunden.
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE442373T1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
BR0009074A (pt) Proteìna para bloquear adesão de plaqueta
ATE298800T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
KR890000666A (ko) 응고활성을 갖는 인자 viii:c-형 분자
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
DE50110182D1 (de) Verwendung von fibrin/fibrinogenpeptiden und -proteinen zur herstellung eines arzneimittels
NO920777L (no) Anti-thrombinpolypeptider
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
Lin et al. Granule proteins of the dental follicle and stellate reticulum inhibit tooth eruption and eyelid opening in postnatal rats
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
BG106513A (en) New class of bioactive glycoproteins

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: OCTAGENE GMBH (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060052755/RJ DE 17/04/2006.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: OCTAPHARMA BIOPHARMACEUTICALS GMBH (DE)

Free format text: NOME ALTERADO DE: OCTAGENE GMBH

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: OCTAPHARMA AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/03/2021